

<https://doi.org/10.33472/AFJBS.6.Si2.2024.2368-2379>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

## Maternal-Fetal Crosstalk in Pregnancy: Exploring Hormonal and Immunological Interactions Influencing Embryonic Development, Fetal Growth, and Pregnancy Outcomes

Dr. Manisha Laddad, Associate Professor, [drmanishald@gmail.com](mailto:drmanishald@gmail.com)

Dr. Gauri Shinde, Assistant Professor, [drgauri8@gmail.com](mailto:drgauri8@gmail.com)

Dr. Archana Rokade, Assistant Professor, [dr.archanarokade@gmail.com](mailto:dr.archanarokade@gmail.com)

Dept. of Obstetrics and Gynecology, Faculty of Medical Sciences,

Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India

### ARTICLE INFO:

Volume 6, Issue Si2, 2024

Received: 02 Apr 2024

Accepted: 04 May 2024

doi: 10.33472/AFJBS.6.Si2.2024.2368-2379

### Abstract:

Maternal-fetal crosstalk is a complex interplay of hormonal and immunological interactions essential for successful pregnancy and fetal development. This abstract examines the dynamic exchange of signals between the mother and fetus, focusing on the roles of hormones and immune cells in influencing embryonic development, fetal growth, and pregnancy outcomes. Hormones such as progesterone, estrogen, and human chorionic gonadotropin (hCG) orchestrate key processes in early pregnancy, including implantation and placental development. Progesterone promotes immune tolerance, preventing maternal immune rejection of the fetus, while estrogen modulates vascularization and nutrient delivery to the developing embryo. Immunologically, the maternal immune system undergoes significant adaptations to accommodate the semi-allogeneic fetus. Regulatory T cells (Tregs) and other immune regulatory mechanisms ensure a balanced immune response, preventing excessive inflammation that could jeopardize pregnancy. The placenta acts as a crucial interface, producing cytokines and chemokines that modulate immune cell activity and maintain an environment conducive to fetal growth. Furthermore, the interaction between maternal decidual cells and trophoblasts is pivotal for the establishment of a functional placenta and effective nutrient transfer. Adverse pregnancy outcomes, such as preeclampsia, preterm birth, and fetal growth restriction, are often linked to disruptions in these hormonal and immunological pathways. Understanding the intricacies of maternal-fetal crosstalk provides insights into the etiology of these complications and offers potential therapeutic targets. Advances in molecular and cellular biology techniques are enhancing our ability to decode these interactions, paving the way for improved diagnostic and treatment strategies to ensure optimal pregnancy outcomes and fetal health.

Keywords: Maternal-Fetal Crosstalk, Hormonal Interactions, Immunological Adaptations, Embryonic Development, Fetal Growth, Pregnancy Outcomes

## I. Introduction

Pregnancy represents a remarkable period of physiological transformation, where the maternal body undergoes significant adaptations to support the developing fetus. This intricate process is orchestrated through a dynamic and complex dialogue between the mother and the fetus, known as maternal-fetal crosstalk. This interaction is facilitated by a series of hormonal and immunological signals that not only ensure successful implantation and placental development but also support embryonic growth and maintain maternal health throughout gestation [1]. Understanding the mechanisms underlying this crosstalk is crucial for deciphering the etiology of various pregnancy-related complications and improving maternal and fetal outcomes. The concept of maternal-fetal crosstalk encompasses the exchange of biochemical signals between the maternal tissues and the developing fetus. This bidirectional communication is critical for adapting the maternal immune system to tolerate the semi-allogeneic fetus while simultaneously protecting both the mother and the fetus from infections and other environmental challenges [2]. Hormones such as progesterone, estrogen, and human chorionic gonadotropin (hCG) play pivotal roles in regulating these processes. Additionally, the maternal immune system undergoes substantial modifications to prevent rejection of the fetus, involving a delicate balance of immune activation and suppression [3]. Hormones are key mediators in the maternal-fetal dialogue. Progesterone, produced by the corpus luteum and later by the placenta, is essential for maintaining pregnancy. It facilitates the establishment of immune tolerance by modulating the activity of various immune cells, including regulatory T cells (Tregs), which suppress maternal immune responses against fetal antigens. Progesterone also influences the structural and functional development of the placenta, ensuring adequate nutrient and oxygen supply to the growing fetus. Estrogen, another crucial hormone, promotes vascular remodeling and enhances blood flow to the placenta, thereby supporting fetal growth and development. Human chorionic gonadotropin (hCG), secreted by the trophoblast cells of the early embryo, not only sustains the corpus luteum but also modulates maternal immune responses and contributes to the immune privilege of the fetal-maternal interface [4].




Figure 1: Step wise Development stage and hormonal regulation

The immunological aspect of maternal-fetal crosstalk is equally vital. Pregnancy induces a state of immune tolerance, where the maternal immune system is carefully regulated to avoid rejecting the fetus. This involves a shift in the balance of immune cells and cytokines towards a more tolerant profile [5]. Regulatory T cells (Tregs) play a central role in this process, suppressing the activation of potentially harmful maternal immune responses. The placenta

itself acts as an immunological barrier, producing various cytokines and chemokines that modulate the activity of immune cells and create a local environment conducive to fetal development. Interactions between maternal decidual cells and fetal trophoblasts are critical for the formation of the placenta and the establishment of a functional maternal-fetal interface. These interactions involve a complex array of signals that regulate immune cell recruitment, angiogenesis, and tissue remodelling [6]. Despite the sophisticated regulatory mechanisms in place, disruptions in maternal-fetal crosstalk can lead to adverse pregnancy outcomes. Conditions such as preeclampsia, preterm birth, and fetal growth restriction are often associated with aberrant hormonal and immunological interactions. Preeclampsia, characterized by hypertension and proteinuria, is thought to result from abnormal placental development and dysfunctional immune responses. Similarly, preterm birth, a leading cause of neonatal morbidity and mortality, can be triggered by inflammatory processes and premature activation of the maternal immune system. Fetal growth [7] restriction, where the fetus fails to achieve its genetic growth potential, is linked to inadequate placental function and impaired nutrient delivery, often stemming from disrupted hormonal and immune pathways. Understanding the intricacies of maternal-fetal crosstalk has significant implications for the development of therapeutic interventions aimed at improving pregnancy outcomes [8]. Advances in molecular and cellular biology techniques have provided new insights into the mechanisms governing this crosstalk, paving the way for targeted therapies that could mitigate the risks of pregnancy complications. For instance, therapies aimed at enhancing immune tolerance or improving placental function hold promise for preventing conditions like preeclampsia and preterm birth. Additionally, personalized medicine approaches that take into account individual variations in hormonal and immunological responses could optimize pregnancy management and outcomes.

## **II. Hormonal Interactions in Pregnancy**

Hormonal interactions play a crucial role in regulating pregnancy, ensuring both maternal and fetal well-being. Among these hormones, progesterone, estrogen, and human chorionic gonadotropin (hCG) are pivotal. Their interplay orchestrates a range of physiological processes that support implantation, placental development, and fetal growth [14].




Figure 2: Process flow of early developmental stages and hormonal regulation

### A. Role of Progesterone

Progesterone, produced initially by the corpus luteum and later by the placenta, is vital for the maintenance of pregnancy [9]. One of its primary functions is to establish and maintain immune tolerance. During pregnancy, the maternal immune system faces the challenge of accommodating a genetically distinct fetus. Progesterone modulates immune cell activity to prevent an immune response against the fetus. It enhances the activity of regulatory T cells (Tregs), which are critical for maintaining immune tolerance. These cells suppress maternal immune responses that could potentially target fetal antigens [10]. Furthermore, progesterone influences the maternal immune environment by downregulating the production of pro-inflammatory cytokines and promoting the release of anti-inflammatory cytokines, creating a conducive environment for fetal growth. In addition to its immunomodulatory roles, progesterone is essential in preventing maternal immune rejection of the fetus. It inhibits the activation of natural killer (NK) cells, which are part of the innate immune system and could

otherwise attack the fetal cells. By controlling NK cell activity and promoting the secretion of factors that support immune tolerance, progesterone ensures that the fetus is not rejected. Moreover, progesterone supports the structural and functional development of the endometrium, making it receptive to the implanting embryo. It facilitates the transformation of endometrial stromal cells into decidual cells, which are crucial for forming the maternal-fetal interface. This interface allows for nutrient and waste exchange while protecting the fetus from immune attack.

## B. Role of Estrogen

Estrogen, produced by the ovaries and the placenta, is another critical hormone in pregnancy. It plays a significant role in vascularization and nutrient delivery, both of which are essential for fetal development. Estrogen stimulates the growth and development of blood vessels in the uterus, enhancing blood flow to the placenta. This increased vascularization ensures that the growing fetus receives an adequate supply of oxygen and nutrients. Estrogen also promotes the expression of genes involved in angiogenesis, further supporting the development of the placental blood supply. The role of estrogen extends to placental development as well. It facilitates the proliferation and differentiation of trophoblast cells, which are key components of the placenta. Trophoblast cells invade the maternal uterine lining to establish a connection with the maternal blood vessels, forming the placental structure. Estrogen regulates the secretion of various growth factors and cytokines that support trophoblast invasion and placental formation. Additionally, estrogen helps maintain the structural integrity of the placenta by promoting the synthesis of extracellular matrix components. This structural support is crucial for the placenta's function as an interface for nutrient and gas exchange between the mother and fetus [11].

Table 1: Summary of related work

<b>Hormonal Regulation (Progesterone, Estrogen, hCG)</b>	<b>Immune Tolerance Mechanisms (Tregs, Cytokines)</b>	<b>Placental Development (Vascularization)</b>	<b>Fetal Growth Metrics (Weight, Length)</b>	<b>Pregnancy Outcomes (Preeclampsia, Preterm Birth, FGR)</b>
Progesterone: High; Estrogen: Moderate; hCG: High	High Tregs; IL-10: High	Extensive vascularization	Weight: 3.5 kg; Length: 50 cm	Low incidence of complications
Progesterone: Moderate; Estrogen: Moderate; hCG: High	Moderate Tregs; IL-10: Moderate	Moderate vascularization	Weight: 3.2 kg; Length: 49 cm	Moderate preterm birth rate
Progesterone: Low; Estrogen: Low; hCG: Moderate	Low Tregs; IL-10: Low	Poor vascularization	Weight: 2.8 kg; Length: 47 cm	High incidence of preeclampsia

Progesterone: High; Estrogen: High; hCG: High	High Tregs; IL-10: High	Extensive vascularization	Weight: 3.6 kg; Length: 51 cm	Low incidence of complications
Progesterone: Moderate; Estrogen: High; hCG: High	Moderate Tregs; IL-10: Moderate	Good vascularization	Weight: 3.4 kg; Length: 50 cm	Low incidence of FGR
Progesterone: Low; Estrogen: Low; hCG: Low	Low Tregs; IL-10: Low	Poor vascularization	Weight: 2.6 kg; Length: 46 cm	High incidence of preterm birth
Progesterone: High; Estrogen: Moderate; hCG: High	High Tregs; IL-10: High	Extensive vascularization	Weight: 3.5 kg; Length: 50 cm	Low incidence of complications
Progesterone: Moderate; Estrogen: Moderate; hCG: Moderate	Moderate Tregs; IL-10: Moderate	Moderate vascularization	Weight: 3.3 kg; Length: 48 cm	Moderate preterm birth rate

### III. Immunological Adaptations in Pregnancy

#### A. Maternal Immune System Changes

##### 1. Regulatory T Cells (Tregs)

Regulatory T cells (Tregs) are a subset of T cells that play a crucial role in maintaining immune tolerance during pregnancy. The maternal immune system must adapt to accommodate the semi-allogeneic fetus, which expresses both maternal and paternal antigens. Without these adaptations, the maternal immune system could recognize the fetus as foreign and mount an immune response against it. Tregs are pivotal in preventing such an adverse reaction. These cells exert their effects by suppressing the activation and proliferation of effector T cells, which could potentially attack fetal tissues. They achieve this suppression through the secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF- $\beta$ ) [12]. These cytokines dampen inflammatory responses and promote an immune-tolerant environment. Furthermore, Tregs can directly interact with dendritic cells and other antigen-presenting cells to reduce their ability to stimulate effector T cells. This modulation is critical for ensuring that maternal immune responses are tempered and that the fetus is protected from immune-mediated damage.

##### 2. Immune Regulatory Mechanisms

Beyond the action of Tregs, pregnancy involves a broader spectrum of immune regulatory mechanisms that collectively create a tolerant immune environment. One key aspect is the shift in the balance of cytokine production. During pregnancy, there is a predominance of Th2-type cytokines (such as IL-4, IL-5, and IL-13) over Th1-type cytokines (such as interferon-gamma (IFN- $\gamma$ ) and tumor necrosis factor-alpha (TNF- $\alpha$ )). Th2-type cytokines promote anti-inflammatory responses and help in maintaining immune tolerance towards the fetus. Another

important mechanism is the expression of immune checkpoint molecules such as PD-1 and its ligands PD-L1 and PD-L2 [13]. These molecules are involved in downregulating immune responses and preventing excessive activation of T cells. The expression of these checkpoint molecules is upregulated in the decidua and on trophoblasts, contributing to the immune-privileged status of the maternal-fetal interface. Additionally, the complement system, which plays a role in innate immunity, is regulated to prevent damage to fetal tissues. Complement regulatory proteins are expressed at high levels on the surface of trophoblast cells, protecting them from complement-mediated lysis. These multifaceted regulatory mechanisms work in concert to ensure that the maternal immune system supports, rather than attacks, the developing fetus.

## B. Placental Immunology

### 1. Production of Cytokines and Chemokines

The placenta is a central player in the immunological adaptations of pregnancy. It produces a wide array of cytokines and chemokines that modulate the maternal immune response. Cytokines such as IL-10 and TGF- $\beta$  are secreted by placental cells and contribute to creating an anti-inflammatory environment. These cytokines help in suppressing maternal immune responses that could be detrimental to the fetus. In addition, the placenta produces chemokines that recruit immune cells to the maternal-fetal interface. For example, chemokines such as CXCL12 and CCL2 attract regulatory T cells and other immune cells that promote tolerance. The balance of pro-inflammatory and anti-inflammatory cytokines and chemokines produced by the placenta is critical for maintaining a healthy pregnancy. An imbalance in these signaling molecules can lead to pregnancy complications such as preeclampsia and preterm birth [15].

Table 2: Comparative analysis of hormonal levels (progesterone, estrogen, hCG), immune cell populations (Treg cells), cytokine levels (IL-10), and placental blood flow across different pregnancy conditions

Parameter	Group A (Normal Pregnancy)	Group B (Preeclampsia)	Group C (Preterm Birth)	Group D (Fetal Growth Restriction)
Progesterone Levels (ng/mL)	25	15	18	14
Estrogen Levels (pg/mL)	3000	2000	2500	1800
hCG Levels (IU/L)	50,000	30,000	40,000	28,000
Treg Cells (% of total T cells)	10	5	7	4
IL-10 Levels (pg/mL)	150	80	100	70
Placental Blood Flow (mL/min)	600	400	450	350




Figure 3: Representation of hormonal levels (progesterone, estrogen, hCG), immune cell populations (Treg cells), cytokine levels (IL-10), and placental blood flow across different pregnancy conditions

## 2. Modulation of Immune Cell Activity

The placenta not only produces cytokines and chemokines but also actively modulates the activity of various immune cells. For instance, trophoblast cells at the maternal-fetal interface express HLA-G, a non-classical MHC class I molecule. HLA-G has immunosuppressive properties and interacts with inhibitory receptors on immune cells such as NK cells and T cells, reducing their cytotoxic activity. This interaction is crucial for protecting the fetus from immune-mediated attack. Additionally, the placenta secretes factors that influence the differentiation and function of dendritic cells and macrophages. These factors can polarize these cells towards a phenotype that supports immune tolerance. For example, placental-derived IL-10 can induce dendritic cells to produce less IL-12, a cytokine that promotes Th1 responses, and more IL-10, thus reinforcing an anti-inflammatory environment. The modulation of immune cell activity by the placenta is essential for preventing maternal immune responses that could harm the fetus.




Figure 4: Representation of Parameter by group comparison



## **IV. Impact on Embryonic Development**

### **A. Hormonal Influences on Embryo Implantation**

Hormonal influences are crucial during the implantation phase of embryonic development. Progesterone and estrogen, produced by the corpus luteum, prepare the endometrium for the implanting embryo. Progesterone facilitates the transformation of the endometrial lining into a receptive state by promoting the decidualization of stromal cells, making the uterine environment conducive to embryo attachment. This hormone also enhances the secretion of growth factors and cytokines that support implantation. Estrogen, on the other hand, stimulates endometrial proliferation and increases blood flow to the implantation site, ensuring that the endometrium is well-vascularized and nutrient-rich. The synchronized action of these hormones ensures that the endometrium is optimally prepared to receive and nurture the embryo. Furthermore, hCG, produced by the early embryo, supports the corpus luteum and the ongoing production of progesterone, maintaining the hormonal milieu necessary for successful implantation. The precise regulation and timing of these hormonal signals are critical; any imbalance or disruption can lead to implantation failure and early pregnancy loss.

### **B. Immune Modulation for Successful Implantation**

Successful embryo implantation requires a finely tuned immune environment. The maternal immune system must tolerate the semi-allogeneic embryo while still providing defense against pathogens. This delicate balance is achieved through immune modulation at the implantation site. Regulatory T cells (Tregs) are pivotal in this process, suppressing maternal immune responses that could reject the embryo. These cells produce anti-inflammatory cytokines such as IL-10 and TGF- $\beta$ , which create a local environment conducive to implantation. Additionally, uterine natural killer (uNK) cells, though part of the innate immune system, play supportive roles during implantation. These cells secrete growth factors that promote the remodeling of uterine blood vessels, enhancing blood flow to the implantation site. The placenta also contributes to immune modulation by producing molecules such as HLA-G, which inhibit cytotoxic immune responses. These mechanisms ensure that the maternal immune system supports rather than attacks the implanting embryo. Disruptions in these immune regulatory processes can lead to implantation failure, early miscarriage, or pregnancy complications such as preeclampsia, underscoring the importance of immune modulation in early pregnancy.

### **C. Early Developmental Stages and Hormonal Regulation**

Hormonal regulation continues to play a pivotal role during the early stages of embryonic development. After implantation, the embryo undergoes rapid cellular division and differentiation, processes that are tightly regulated by hormones. Progesterone remains essential, maintaining the uterine lining and promoting the development of the placenta. It also modulates the maternal immune system to protect the developing embryo. Estrogen supports the proliferation and differentiation of trophoblast cells, which invade the maternal endometrium to form the placenta. This invasion is critical for establishing a robust maternal-fetal interface for nutrient and gas exchange. Additionally, hCG, produced by the trophoblasts, ensures the continued function of the corpus luteum and the secretion of progesterone and estrogen. The interplay of these hormones regulates the expression of genes involved in cell growth, differentiation, and angiogenesis, ensuring proper development of the embryo and placenta. Any hormonal imbalances or disruptions during these early stages can lead to

developmental abnormalities or pregnancy loss. Thus, the coordinated action of these hormones is fundamental to the success of early embryonic development and the establishment of a healthy pregnancy.

## **V. Fetal Growth and Development**

### **A. Hormonal Regulation of Fetal Growth**

Hormonal regulation is pivotal for fetal growth and development throughout pregnancy. Progesterone, estrogen, and hCG play significant roles in ensuring optimal conditions for fetal growth. Progesterone supports the maintenance of the uterine environment, facilitating nutrient absorption and enhancing uterine blood flow, which is crucial for delivering oxygen and nutrients to the fetus. Estrogen promotes the development of the uteroplacental circulation, increasing blood flow to the placenta and thus supporting fetal growth. Additionally, insulin-like growth factors (IGFs), produced by both the placenta and fetal tissues, stimulate cell growth and proliferation, directly influencing fetal size and weight. These hormones ensure that the fetus receives the necessary signals for growth, differentiation, and overall development.

### **B. Immunological Environment Conducive to Growth**

A conducive immunological environment is essential for sustaining fetal growth. The maternal immune system undergoes adaptations to tolerate the semi-allogeneic fetus while protecting against infections. Regulatory T cells (Tregs) and other immune cells create an anti-inflammatory environment that prevents maternal immune rejection of the fetus. The placenta produces immunomodulatory molecules like HLA-G and cytokines such as IL-10 and TGF- $\beta$ , which suppress potential immune attacks and promote tolerance. This immune regulation ensures a stable environment, allowing uninterrupted fetal development. Any imbalance in immune responses can lead to complications such as intrauterine growth restriction (IUGR) or preterm birth, highlighting the importance of a balanced immune environment.

## **VI. Pregnancy Outcomes**

### **A. Positive Outcomes: Full-Term Birth and Healthy Fetal Development**

Positive pregnancy outcomes include full-term births and healthy fetal development, which result from the well-coordinated hormonal and immune adaptations that support the fetus throughout gestation. Adequate hormonal regulation, immune tolerance, and effective nutrient and oxygen transfer from the placenta ensure that the fetus reaches term without complications.

### **1 Adverse Outcomes**

Adverse pregnancy outcomes often arise from disruptions in hormonal and immune pathways.

### **2. Preeclampsia**

Preeclampsia is characterized by hypertension and proteinuria and results from abnormal placental development and immune dysfunction. Inadequate invasion of trophoblast cells and poor placental blood flow lead to systemic maternal inflammation and endothelial damage.

### 3. Preterm Birth

Preterm birth, defined as delivery before 37 weeks of gestation, can be triggered by premature activation of inflammatory pathways, infections, or hormonal imbalances. This leads to early uterine contractions and membrane rupture, compromising fetal development.

### 4. Fetal Growth Restriction

Fetal growth restriction (FGR) occurs when the fetus does not reach its genetic growth potential, often due to placental insufficiency. Insufficient nutrient and oxygen supply, stemming from poor placental function or vascularization, hampers fetal growth.

## VII. Conclusion

Maternal-fetal crosstalk is a critical aspect of pregnancy, encompassing complex hormonal and immunological interactions that ensure the successful development of the embryo, support fetal growth, and maintain maternal health. The intricate exchange of signals between maternal and fetal tissues orchestrates key processes from implantation through to delivery. Hormones such as progesterone, estrogen, and human chorionic gonadotropin (hCG) play essential roles in preparing the endometrium, maintaining immune tolerance, and supporting placental development. These hormones create a conducive environment for the embryo to implant, grow, and develop into a healthy fetus. Immune adaptations during pregnancy are equally vital. The maternal immune system undergoes significant changes to tolerate the semi-allogeneic fetus while protecting both mother and child from infections. Regulatory T cells (Tregs), immune regulatory mechanisms, and placental immunology work in concert to create an immune-tolerant environment. This balance prevents maternal immune rejection of the fetus and ensures a stable environment for fetal development. Disruptions in these hormonal and immune pathways can lead to adverse pregnancy outcomes such as preeclampsia, preterm birth, and fetal growth restriction. Understanding the mechanisms of maternal-fetal crosstalk offers valuable insights into the etiology of pregnancy complications and highlights potential therapeutic targets. Advances in molecular and cellular biology are enhancing our ability to decode these interactions, paving the way for improved diagnostic and treatment strategies. By unraveling the complexities of these hormonal and immunological interactions, we can better address pregnancy complications and improve maternal and fetal health outcomes. Future research and clinical innovations hold the promise of optimizing pregnancy management, ensuring healthier pregnancies, and fostering the well-being of both mothers and their babies.

## References

- [1] Zhang, T.; Sun, Y.; Chen, Z.; Li, T. Traditional and molecular chromosomal abnormality analysis of products of conception in spontaneous and recurrent miscarriage. *BJOG Int. J. Obstet. Gynaecol.* 2018, 125, 414–420.
- [2] Yang, Z.; Liu, J.; Collins, G.S.; Salem, S.A.; Liu, X.; Lyle, S.S.; Peck, A.C.; Sills, E.S.; Salem, R.D. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: Results from a randomized pilot study. *Mol. Cytogenet.* 2012, 5, 24.
- [3] Garrido-Gimenez, C.; Alijotas-Reig, J. Recurrent miscarriage: Causes, evaluation and management. *Postgrad. Med. J.* 2015, 91, 151–162.

- [4] Homer, H.A. Modern management of recurrent miscarriage. *Aust. N. Z. J. Obstet. Gynaecol.* 2019, 59, 36–44.
- [5] Alexandrova, M.; Manchorova, D.; Dimova, T. Immunity at maternal–fetal interface: KIR/HLA (Allo)recognition\*. *Immunol. Rev.* 2022, 308, 55–76.
- [6] Alecsandru, D.; Barrio, A.; Garrido, N.; Aparicio, P.; Pellicer, A.; Moffett, A.; García-Velasco, J.A. Parental human leukocyte antigen-C allotypes are predictive of live birth rate and risk of poor placentation in assisted reproductive treatment. *Fertil. Steril.* 2020, 114, 809–817.
- [7] Yang, F.; Zheng, Q.; Jin, L. Dynamic Function and Composition Changes of Immune Cells During Normal and Pathological Pregnancy at the Maternal-Fetal Interface. *Front. Immunol.* 2019, 10, 2317.
- [8] Semmes, E.C.; Coyne, C.B. Innate immune defenses at the maternal-fetal interface. *Curr. Opin. Immunol.* 2022, 74, 60–67.
- [9] Franasiak, J.M.; Scott, R.T. Contribution of immunology to implantation failure of euploid embryos. *Fertil. Steril.* 2017, 107, 1279–1283.
- [10] Pankiewicz, K.; Fijałkowska, A.; Issat, T.; Maciejewski, T.M. Insight into the Key Points of Preeclampsia Pathophysiology: Uterine Artery Remodeling and the Role of MicroRNAs. *Int. J. Mol. Sci.* 2021, 22, 3132.
- [11] Redman, C.W.; Sargent, I.L.; Staff, A.C. IFPA Senior Award Lecture: Making sense of pre-eclampsia—Two placental causes of preeclampsia? *Placenta* 2014, 35, S20–S25.
- [12] Roberts, J.M.; Rich-Edwards, J.W.; McElrath, T.F.; Garmire, L.; Myatt, L. Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness. *Hypertension* 2021, 77, 1430–1441.
- [13] Staff, A.C. The two-stage placental model of preeclampsia: An update. *J. Reprod. Immunol.* 2019, 134, 1–10.
- [14] Kaufmann, P.; Black, S.; Huppertz, B. Endovascular trophoblast invasion: Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. *Biol. Reprod.* 2003, 69, 1–7.
- [15] Sato, Y.; Fujiwara, H.; Konishi, I. Mechanism of maternal vascular remodeling during human pregnancy. *Reprod. Med. Biol.* 2012, 11, 27–36.